Yep. In their current pool of just paediatric patients, Cynata's target market is 6.6x bigger (2500 vs 375 patients p.a.). Even with a label extension to adults as a third line therapy, Cynata's market is 3.3x larger.
And to @pfeifer1982's point, the P word is sacrilege on the M side of town
But just think about it just from an administrative perspective. 8 infusions spread across 4 weeks is just asking for something to go wrong. Instead compare with Cynata's treatment, which just asks for two infusions on days 0 and 4. So much simpler because it's so much more potent. That's worth paying more for, right?
CYP Price at posting:
24.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)